# US 8,784,828 B2 · Ehrlichia ewingii proteins, nucleic acids, and methods of their use > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,784,828 B2 - Document ID: US8784828B2 - Status: Granted - Kind: B2 - Application number: 12/115,490 - Filed: 2008-05-05 - Published: 2009-01-08 - Granted: 2014-07-22 - Earliest claimed: 2007-05-04 - Assignees: The Ohio State University Research Foundation - Applicants: Yasuko Rikihisa - Inventors: Yasuko Rikihisa - Web page: https://patentgrep.com/patent/US8784828B2 ## CPC - A61K 39/0233: {Rickettsiales, e.g. Anaplasma} - A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55}) - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - C07K 14/29: from Richettsiales (O) - G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor - G01N 33/56911: {Bacteria} - G01N 33/6854: {Immunoglobulins} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 2039/552: {Veterinary vaccine} - A61K 2039/575: {humoral response} - A61K 2039/6031: {Proteins} - G01N 2333/29: from Richettsiales (o) - G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The novel omp-1 gene cluster encoding twenty one Ehrlichia ewingii (EE) proteins was isolated and sequenced completely. This invention relates to isolated E. ewingii (EE) polypeptides, isolated polynucleotides encoding EE polypeptides, probes, primers, isolated antibodies and methods of their production, immunogenic compositions and vaccines, as well as methods of using the EE polypeptides, antibodies, probes, and primers for the purpose of diagnosis, therapy and production of vaccines against E. ewingii. ## Claims ### Claim 1 An isolated OMP-1-14 E. ewingii polypeptide consisting of a sequence that is at least 85% identical to amino acids 26 to 285 of SEQ ID NO: 17. ### Claim 2 (depends on 1) The isolated polypeptide of claim 1, wherein the polypeptide consists of a sequence that is at least 90% identical to amino acids 26 to 285 of SEQ ID NO: 17. ### Claim 3 (depends on 1) The isolated polypeptide of claim 1, wherein the polypeptide consists of a sequence that is at least 95% identical to amino acids 26 to 285 of SEQ ID NO: 17. ### Claim 4 (depends on 1) The isolated polypeptide of claim 1, wherein the polypeptide consists of amino acids 26 to 285 of SEQ ID NO: 17. ### Claim 5 (depends on 1) The isolated polypeptide of claim 1, wherein the polypeptide contains an immunoreactive fragment that is 6 or more consecutive amino acids from the following sequences: (1) SEQ ID NO: 150; (2) SEQ ID NO: 169; (3) SEQ ID NO: 187; (4) SEQ ID NO: 222; or any combination of the sequences (1)-(4). ### Claim 6 (depends on 5) The isolated polypeptide of claim 5, wherein the immunoreactive fragment is the amino acid sequence of SEQ ID NO: 38. ### Claim 7 (depends on 4) The isolated polypeptide of claim 4, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 17. ### Claim 8 (depends on 1) An immunogenic composition comprising a polypeptide according to claim 1 and a pharmaceutically acceptable carrier, wherein said composition is capable of producing antibodies specific to E. ewingii in a subject to whom the composition has been administered. ### Claim 9 (depends on 8) The immunogenic composition of claim 8, wherein the polypeptide is operatively linked to an N-terminal or C-terminal peptide or tag. ### Claim 10 (depends on 8) The immunogenic composition of claim 8, wherein the polypeptide consists of a sequence that is at least 90% identical to amino acids 26 to 285 of SEQ ID NO: 17. ### Claim 11 (depends on 8) The immunogenic composition of claim 8, wherein the polypeptide consists of a sequence that is at least 95% identical to amino acids 26 to 285 of SEQ ID NO: 17. ### Claim 12 (depends on 8) The immunogenic composition of claim 8, wherein the polypeptide consists of amino acids 26 to 285 of SEQ ID NO: 17. ### Claim 13 (depends on 8) The immunogenic composition of claim 8, wherein the polypeptide contains an immunoreactive fragment that is 6 or more consecutive amino acids from the following sequences: (1) SEQ ID NO: 150; (2) SEQ ID NO: 169; (3) SEQ ID NO: 187; (4) SEQ ID NO: 222; or any combination of the sequences (1)-(4). ### Claim 14 (depends on 13) The immunogenic composition of claim 13, wherein the immunogenic fragment has at least 6 amino acids that are bacterial surface exposed. ### Claim 15 (depends on 1) A kit for detecting antibodies specific for E. ewingii, the kit comprising a polypeptide according to claim 1, and one or more reagents for detecting interactions between the polypeptide according to claim 1 and antibodies specific for E. ewingii in a test sample. ### Claim 16 (depends on 15) The kit of claim 15, wherein the polypeptide consists of amino acids 26 to 285 of SEQ ID NO: 17.